Vaccines

Vaccines

Vaccine Immunotherapy for Patients with Glioblastoma Multiforme

By
Al Musella, DPM
Last Updated 1/24/10

Vaccine Trials

This is a list of the vaccine trials we know about (all brain tumor types). If you know of any we missed - or if any of these closed, let us know!, as these change rapidly

Treatment Next 25 Location Last Updated

Details A Study of ICT-107(Vaccine therapy) in Glioblastoma Multiforme (GBM) Birmingham, AL
Tucson, AZ
La Jolla, CA
Los Angeles, CA
Tampa, FL
Chicago, IL
Chicago, IL
Louisville, KY
Winston-Salem, NC
Edison, NJ
New Brunswick, NJ
Summit, NJ
Great Neck & Commack, NY
Cleveland, OH
Cleveland, OH
Hershey, PA
Philadelphia, PA
Dallas, TX
Houston, TX
Charlottesville, VA 02/26/2012

Details Phase 2 Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma Lenexa, KS 06/09/2011

Details Dendritic Cell Cancer Vaccine for High-grade Glioma Innsbruck, Austria 05/05/2011

Details A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors New York, NY 03/10/2011

Details Dendritic Cell Vaccine for Patients With Brain Tumors Los Angeles, CA 09/21/2010

Details A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Newly Diagnosed Malignant or Intrinsic Brain Stem Gliomas (BSG) or Incompletely Resected Non-Brainstem High-Grade Gliomas (HGG) or Recurrent Unresectable Low-Grade Gliomas (LGG) or Recurrent High Grade Gliomas Pittsburgh, PA 03/31/2010

Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Los Angeles, CA
Los Angeles, CA
Orange, CA
Palo Alto, CA
San Francisco, CA
New Haven, CT
Gainsville, FL
Jacksonville, FL
Atlanta, GA
Chicago, IL
Chicago, IL
Chicago, IL
Evanston, IL
Boston, MA
Baltimore, MD
Detroit, MI
Lansing, MI
Saginaw, MI
Durham, NC
Hackensack, NJ
Buffalo, NY
New York, NY
New York, NY
Syracuse, NY
Cleveland, OH
Cleveland, OH
Columbus, OH
Philadelphia, PA
Houston, TX
San Antonio, TX
Salt Lake City, UT
Charlottesville, VA
Seattle, WA 03/09/2010

Details Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia Durham, NC 01/24/2010

Details Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-Specific T-Cell Adoptive Transfer [ERaDICATe] Durham, NC 01/24/2010

Details Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma Los Angeles, CA 01/24/2010

Details Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients Los Angeles, CA 01/24/2010

Details Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma San Francisco, CA 01/24/2010

Details PHASE II, Single-arm, Open-label Investigation of HSPPC-96 Vaccine With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme San Francisco, CA 01/24/2010

Details Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme Durham, NC 01/24/2010

Details Phase I Study of Intratumoral and/or Resection Cavity Administration of Recombinant Measles Virus Encoding Human Carcinoembryonic Antigen in Patients With Recurrent Glioblastoma Multiforme Rochester, MN 01/24/2010

Details Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor Boston, MA 09/06/2009

Details PHASE II, single-arm, open-label investigation of HSPPC-96 vaccine with concurrent temozolomide in patients with newly diagnosed Glioblastoma Multiforme San Francisco, CA 07/07/2009

Details A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Adults with High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas Pittsburgh, PA 01/06/2009

Details A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma Los Angeles, CA 03/02/2008

Details A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma Los Angeles, CA 03/02/2008

Details Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) Los Angeles, CA 03/02/2008

Literature Cited:

1. Yang MY, Zetler PM, Prins RM, et al., “Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications.” Expert Rev. Neurotherapeutics. 2006; 6(10):1481-1494.

2. Williams BA, “Treatment Options for Glioblastoma and Other Gliomas”, 2007. http://virtualtrials.com/pdf/williams2007.pdf

3. Prins RM, Liau LM, “Immunology and immunotherapy in neurosurgical disease.” Neurosurgery. 2003; 53:144-152.

4. Walker PR, Calzascia T, Dietrich PV, “All in the head: obstacles for immune rejection of brain tumours.” Immunology. 2002; 107: 28-38.

5. Walker PR, Calzascia T, Schnuriger V, et al., The brain parenchema is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol. 2000; 165:3128-3135.

6. Smits HA, van Beelen AJ, de Vos NM, et al., Activation of human macrophages by amyloid-B is attenuated by astrocytes. J Immunol. 2001; 166: 6869-6876.

7. Taniguchi Y, Ono K, Yoshida S, Tanaka R., “Antigen presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J Neuroimmunol. 2000; 111: 177-185.

8. Adams GP, Weiner JM, “Monoclonal antibody therapy of cancer.” Nat Biotechnol. 2005; 23: 1147-1157.

9. Sampson JH, Crotty LE, Lee S, et al., “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.” Proc Natl Acad Sci. 2000; 97: 7503-7508.

10. Wikstrand CJ, Zalutsky MR, Bigner DD. “Radiolabeled antibodies for therapy for brain tumors.” In: Brain Tumor Immunotherapy, Human Press, NJ, USA, 2001: 205-209.

11. Riva P, Franceschi G, Frattarelli M, et al., “Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study.” Clin Cancer Res. 1999; 5: S3275-S3280.

12. Reardon DA, Akabani G, Coleman RE, et al., “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol. 2002; 20: 1389-1397.

13. Emrich JG, Brady LW, Quang TS, et al., “Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. 2002; Am J Clin Oncol 25: 541-546.

14. Quang TS, Brady LW, “Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high grade gliomas. Int J Radiat Oncol Biol Phys. 2004; 58: 972-975.

15. Paganelli G, Bartolomei M, Ferrari M, et al., “Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results.” Cancer Biother Radiopharm. 2001; 16: 227-235.

16. Bartolomei M, Mazzetta C, Hadnkiewicz-Junal D, et al., “Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.” Q J Nucl Med Mol Imaging. 2004; 48: 220-228.

17. Hall WA, “Targeted toxin therapy for malignant astrocytoma. Neurosurgery. 2000; 46: 544-551.

18. Rand RW, Kreitman RJ, Patronas N, et al., “Intratumorial administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res. 2000; 6: 2157-2165.

19. Kunwar S, “Convection-enhanced delivery of IL13PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Act Neurochir Suppl. 2003; 88: 105-111.

20. Parney IF, Kunwar S, McDermott M, et al., “Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005; 102: 267-275.

21. Sampson JH, Akabain G, Archer GE, et al., “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth facto (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003; 65: 27-35.

22. Husain SR, Joshi BH, Puri RK, “Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer. 2001; 92: 168-175.

23. Husain SR, Puri RK, “Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol. 2003; 65: 37-48.

24. Kunwar S, Chang SM, Prados MD, et al., “Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotoz in early-phase studies. Neurosurg Focus. 2006; 20: E15.

25. Shimamura T, Husain SR, Puri RK, “The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.” Neurosurg Focus. 2006; 20: E11.

26. Plautz GE, Mukai S, Cohen PA, Shu S, “Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol. 2000; 165: 3656-3662.

27. Mitchell DA, Fecci PE, Sampson JH, “Adoptive immunotherapy for malignant glioma. Cancer J. 2003; 9: 157-166.

28. Dillman RO, Duma CM, Schiltz PM, et al., “Intracavity placement of autologous lymphokine-activated killer (LAK( cells after resection of recurrent glioblastoma. J Immunother. 2004; 27: 398-404.

29. Hayes RL, Arbit E, Odaimi M, et al., “Adoptive cellular immunotherapy for the treatment of malignant gliomas.” Crit Rev Oncol Hematol. 2001; 39: 31-42.

30. Kruse CA, Cepeda L, Owens B, et al., “Treatment of recurrent glioma with intracavity alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997; 45: 77-87.

31. Merchant RE, Baldwin NG, Rice CD, Bear HD, “Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol Res. 1997; 19: 145-152.

32. Wood CW, Holladay FP, Turner T, et al., “A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol. 2000; 48: 113-120.

33. Ishikawa E, Tsuboi K, Saijo K, et al., Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004; 24: 1861-1871.

34. Quattrocchi KB, Miller CH, Cush S, et al., “Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999; 45; 141-157.

35. Wang LX, Huang WX, Graor H, et al., “Adoptive immunotherapy of caner with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med. 2004; 2; 41.

36. Liau LM, Black KL, Prins RM, et al., “Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.” J Neurosurg. 1999; 90; 1115-1124.

37. Okada H, Pollack IF, “Cytokine gene therapy for malignant glioma.” Exper Opin Biol Ther. 2004; 4; 1609-1620.

38. Glick RP, Lichtor T, Cohen EP, “Cytokine-based immune-gene therapy for brain tumors. In: Brain Tumor Immunotherapy, Humana Press, NJ, USA, 2001; 273-288.

39. Yu J. S., et al., “Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.” Cancer Res. 2001; 61: 842-847.

40. Liau LM, Prins RM, Kiertscher SM, et al., “Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local CNS tumor microenvironment.” Clin Cancer Res. 2005; 11: 5515-5525.

41. Yu JS, Liu G, Ying H, et al., “Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.” Cancer Res. 2004; 64: 4973-4979.

42. Yu JS, Wheeler CJ, Zeltzer PM, et al., “Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.” Cancer Res. 2001; 61: 842-847.

43. Yamanaka R, Abe T, Yajima N, et al., “Vaccination of recurrent glioma patients with tumour lysat-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial.” Br J Cancer. 2003; 89: 1172-1179.

44. Yamanaka R, Homma J, Yajima N, et al., “Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II Trial. Clin Cancer Res. 2005; 11: 4160-4167.

45. Kikuchi T, Akasaki Y, Irie M, et al., “Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.” Cancer Immunol Immunother. 2001; 50: 337-344.

46. Kikuchi T, Akasaki Y, Abe T, et al., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004; 27: 452-459.

47. Wheeler, CJ et al., “Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.” Clin Cancer Res. 2004; 10: 5316-5326.

48. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ., “Live bacteria as the basis for immunotherapies against cancer. Expert Rev Vaccines. 2002; 1: 495-505.

49. Glick RP, Lichtor T, Cohen EP, “Cytokine immunogene therapy.” Neurosurg Focus. 2000; Dec 15; 9(6): e2.

50. Glick RP, Lichtor T, Lin H, et al., “Immunogene therapy as a treatment for malignant brain tumors in young mice.” J Neurosurg. 2006; 105: 65-77.

51. Okada H, Lieberman FS, Edington HD, et al., “Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neuroonco. 2003; 64: 13-20.

52. Ren H, Boulikas T, Lundstrom K, et al., “Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semlik forest virus vector carrying the human interleukin-12 gene – a Phase I/II clinical protocol. J Neurooncol. 2003; 147-154.

53. Matzinger P, “The danger model: a renewed sense of self.” Science. 2002; 296: 301-305.

54. Barton GM, Medzhitov R., “Toll-like receptors and their ligands.” Curr Top Microbiol Immunol. 2002; 270: 81-92.

55. Ulevitch RJ., “Therapeutics targeting the innate immune system.” Nat Rev Immunol. 2004; 4: 512-520.

56. Liau LM, Jensen ER, Kremen TJ, et al., “Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogene vaccination. Cancer Res. 2002; 62: 2287-2293.

57. Calzascia T, Di Berardino-Besson W, Wilmotte R, et al., “Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol. 2003; 171: 2187-2191.

58. Wilcox ME, et al., “Reovirus as an oncolytic agent against experimental human malignant gliomas. J Nat Cancer Inst. 2001; 93: 903-912.

59. Gromeier, M, et al., “Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Nat Acad Sci. 2000; 97: 6803-6808.

60. Rosenberg sA, Spiess PJ, Kleiner DE., “Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother. 2002; 25: 218-225.

61. Csatary LK, Gosztonyi G, Szeberenyi J, et al., “MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol. 2004; 67: 83-93.

62. Germano IM, et al., “Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol. 2003; 65: 279-289.

63. Steiner HH, Bonsanto MM, Beckhove P, et al., “Antitumor vaccination of patients with glioblastoma multimform: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004; 22: 4272-4282.

64. Rampling R, et al., “Toxicity evaluation of replication-competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7: 859-866.

65. Heimberger AB, et al., “An epidermal growth factor receptor variant III peptide vaccination appears promising in newly diagnosed GBM patients. 2006. Paper presented at American Association of Neurological Surgeons. .